Not a traditional drug phase: Psychosocial Intervention for Parental Caregivers of AYA with Cancer for Caregiving for Cancer
The study team aims to adapt a psychosocial intervention to reduce psychological distress among the caregiving parents of adolescents and young adults (aged 15-39) who have cancer. First, the study team will adapt an evidence-supported, group-based program for improving psychological resiliency (Stress Management and Resiliency Training - Relaxation Response Resiliency Program; SMART-3RP (E.
Official registry: https://clinicaltrials.gov/study/NCT07139769 · Zeba Ahmad, Ph.D. · enrollment listed as 48
What this phase means
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Psychosocial Intervention for Parental Caregivers of AYA with Cancer. The registry lists allocation as na. The study team aims to adapt a psychosocial intervention to reduce psychological distress among the caregiving parents of adolescents and young adults (aged 15-39) who have cancer.
They plan to enroll about 48 people at Boston. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.
Official title (unrewritten)
The RAISE Study: Adapting Psychosocial Resiliency Intervention for Parents of Adolescents and Young Adults With Cancer
Interventions: Psychosocial Intervention for Parental Caregivers of AYA with Cancer
Primary outcome (registry wording): Intervention Feasibility: Percent of Identified Prospective Participants Who Enroll
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Self-identifying parent/guardian who provides a primary informal caregiving role in their child's cancer
- Recipient of caregiving is aged between 15 and 39 years and is receiving treatment for cancer at the Mass General Brigham Cancer
- Participant must score equal to or greater than 2 (out of a possible 10) on the National Comprehensive Cancer Network Distress Thermometer
Who the registry excludes
- Active symptoms of psychosis or suicidal ideation that would preclude safe participation
Public study contact (from the registry)
Zeba N Ahmad, Ph.D.
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- Mass General Brigham Cancer Institute at Massachusetts General Hospital — Boston, Massachusetts (recruiting)
FAQ about this NCT record
Is NCT07139769 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07139769?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07139769?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary